3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
50
Stomach Neoplasms
13
Colonic Neoplasms
5
Rectal Neoplasms
4
Sarcoma
3
Neoplasms
2
Neoplasm Metastasis
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Hepatocellular
2
Advanced Colorectal Carcinoma
2
Unresectable Metastatic Colorectal Cancer
1
To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
1
TAS 102
1
Sarcoma, Ewing
1
Platinum Resistant Ovarian Cancer
1
Patients With Advanced Metastatic Colorectal Cancer
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm, Residual
1
Metastatic Colorectal Adenocarcinoma
1
Metastasis Colorectal Cancer
1
Locally Advanced Rectal Cancer
1
HER2-positive Gastric Cancer
1
Gastric Cancer Adenocarcinoma Metastatic
1
Fruquintinib
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Cancer Metastatic
1
Colorectal Adenocarcinoma
1
Carcinoma, Renal Cell
1
Interventions
toripalimab
1
donafenib
1
Oxaliplatin
1
HMPL-013
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Biliary Tract Adenocarcinoma
×
HMPL-013
×
Clear all
NCT04156958
2019-11-08
FSTAMBTA
Sichuan University
Phase 2
Unknown
33 enrolled